Skip to main content
SpringerLink
Log in

Medical and Psychiatric Comorbidities: Complicating Treatment Expectations

  • Chapter
  • First Online:
Treatment–Refractory Schizophrenia

  • 1420 Accesses

Abstract

Upon all outcomes, premature mortality is a profound consequence of medical and psychiatric (especially depression with suicidality) comorbidities. Additionally, obesity and metabolic disturbances substantially complicate the selection and duration of trial of subsequent antipsychotic medications. This is most pronounced with respect to clozapine, wherein obesity and metabolic dysfunction now predominate and powerful influence the use of this drug as well as adjunctive therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ahmed M, Hussain I, O’Brien SM, Dineen B, Griffin D, McDonald C (2008) Prevalence and associations of the metabolic syndrome among patients prescribed clozapine. Ir J Med Sci 177(3):205–210

    Article  CAS  PubMed  Google Scholar 

  • Annamraju S, Sheitman B, Saik S, Stephenson A (2007) Early recognition of clozapine-induced myocarditis. J Clin Psychopharmacol 27:479–483

    Article  CAS  PubMed  Google Scholar 

  • Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW (2011) Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses 5(1):17–25

    Article  PubMed  Google Scholar 

  • Baptista T, ElFakih Y, Uzcátegui E, Sandia I, Tálamo E, Araujo de Baptista E, Beaulieu S (2008) Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22(6):477–495

    Article  CAS  PubMed  Google Scholar 

  • Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D (2012) Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 37(12):1901–1911

    Article  CAS  PubMed  Google Scholar 

  • Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE (2002) Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry 63(4):345–348

    Article  CAS  PubMed  Google Scholar 

  • Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI (2006) Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 32(4):637–643

    Article  PubMed Central  PubMed  Google Scholar 

  • Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W (2010) Schizophrenia patient outcomes research team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71–93

    Article  PubMed Central  PubMed  Google Scholar 

  • Buckley P, Miller B, Lehrer D, Castle DJ (2009) Psychiatric comorbidities and schizophrenia. Schizophr Bull 35(2):383–402

    Article  PubMed Central  PubMed  Google Scholar 

  • Carrizo E, Fernández V, Quintero J, Connell L, Rodríguez Z, Mosquera M (2008) Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr Res 103(1–3):83–93

    Article  PubMed  Google Scholar 

  • Carrizo E, Fernández V, Connell L, Sandia I, Prieto D, Mogollón J, Valbuena D, Fernández I, de Baptista EA, Baptista T (2009) Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 113(1):19–26

    Article  PubMed  Google Scholar 

  • Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA (2003) Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361:393–395

    Article  CAS  PubMed  Google Scholar 

  • Chen DC, Qi LY, Xiu MH, Cao LY, Wang F, Chen S, Wu GY, Kosten TA, Kosten TR, Zhang XY (2008) Elevated serum levels of tumor necrosis factor-α in clozapine-associated obesity in chronic schizophrenia. Schizophr Res 106(2–3):367–368

    Article  PubMed  Google Scholar 

  • Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF (2012) Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry 73(10):1307–1312

    Article  CAS  PubMed  Google Scholar 

  • Coodin S, Ballegeer T (2000) Clozapine therapy and pulmonary embolism. Can J Psychiatry 45:395

    CAS  PubMed  Google Scholar 

  • Das C, Mendez G, Jagasia S, Labbate LA (2012) Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry 24(3):225–239

    PubMed  Google Scholar 

  • De Hert M, Correll CU, Cohen D (2010) Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 117(1):68–74

    Article  PubMed  Google Scholar 

  • Devaraj S, Valleggi S, Siegel D, Jialal I (2010) Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atheroscler Rep 12:110–118

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Dieset I, Hope S, Ueland T, Bjella T, Agartz I, Melle I, Aukrust P, Røssberg JI, Andreassen OA (2012) Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. Schizophr Res 140(1–3):169–174

    Article  PubMed  Google Scholar 

  • Drake RE, Xie H, McHugo GJ et al (2000) The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 26(2):441–449

    Article  CAS  PubMed  Google Scholar 

  • Ehret M, Goethe J, Lanosa M, Coleman CI (2010) The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry 71(10):1286–1292

    Article  PubMed  Google Scholar 

  • Fan X, Liu EY, Freudenreich O, Park JH, Liu D, Wang J, Yi Z, Goff D, Henderson DC (2010) Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr Res 118:211–217

    Article  PubMed  Google Scholar 

  • Fawzi MH, Fawzi MM, Fawzi MM, Said NS (2011) C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res 190(1):91–97

    Article  CAS  PubMed  Google Scholar 

  • Fernandez-Egea E, Bernardo M, Heaphy CM, Griffith JK, Parellada E, Esmatjes E, Conget I, Nguyen L, George V, Stöppler H, Kirkpatrick B (2009) Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr Bull 35(2):437–442

    Article  PubMed Central  PubMed  Google Scholar 

  • Fontain KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, Allison DB (2001) Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 101:277–288

    Article  Google Scholar 

  • Galassi A, Reynolds K, He J (2006) Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 119:812–819

    Article  CAS  PubMed  Google Scholar 

  • Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) American heart association; national heart, lung, and blood institute diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 112:2735–2752

    Article  PubMed  Google Scholar 

  • Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L, Stephan K, McNeil J (2007) Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 30(1):47–57

    Article  CAS  PubMed  Google Scholar 

  • Hägg S, Lindblom Y, Mjörndal T, Adolfsson R (2006) High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 21(2):93–98

    Article  PubMed  Google Scholar 

  • Hahn MK, Remington G, Bois D, Cohn T (2010) Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. J Clin Psychopharmacol 30(6):706–710

    Article  CAS  PubMed  Google Scholar 

  • Hamner MB (1996) Clozapine treatment for a veteran with comorbid psychosis and PTSD. Am J Psychiatry 153(6):841

    CAS  PubMed  Google Scholar 

  • Harris EC, Barraclough B (1998) Excess mortality of mental disorder. Br J Psychiatry 173:11–53

    Article  CAS  PubMed  Google Scholar 

  • Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D (2004) Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 65(5):686–689

    Article  CAS  PubMed  Google Scholar 

  • Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Evins AE, Cather C, Goff DC (2005) Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 66(9):1116–1121

    Article  CAS  PubMed  Google Scholar 

  • Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, Zhang H, Hayden D, Freudenreich O, Cather C, Evins AE, Goff DC (2007) A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 115(2):101–105

    Article  CAS  PubMed  Google Scholar 

  • Hennen J, Baldessarini RJ (2005) Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 73(2–3):139–145

    Article  PubMed  Google Scholar 

  • Hoang U, Stewart R, Goldacre MJ (2011) Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ 343:d5422

    Article  PubMed Central  PubMed  Google Scholar 

  • Kao HT, Cawthon RM, Delisi LE, Bertisch HC, Ji F, Gordon D, Li P, Benedict MM, Greenberg WM, Porton B (2008) Rapid telomere erosion in schizophrenia. Mol Psychiatry 13(2):118–119

    Article  CAS  PubMed  Google Scholar 

  • Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375:132–140

    Article  PubMed  Google Scholar 

  • Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim JC, Warren KR, Conley RR (2010) Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry 71(3):304–311

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kelly TM, Daley DC, Douaihy AB (2012) Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav 37(1):11–24

    Article  PubMed Central  PubMed  Google Scholar 

  • Kluge M, Schuld A, Schacht A, Himmerich H, Dalal MA, Wehmeier PM, Hinze-Selch D, Kraus T, Dittmann RW, Pollmächer T (2009) Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 34(1):118–128

    Article  CAS  PubMed  Google Scholar 

  • Ko YH, Joe SH, Jung IK, Kim SH (2005) Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 28(4):169–175

    Article  CAS  PubMed  Google Scholar 

  • Leo CA (1979) Therapeutic effects of clozapine. A 4-year follow-up of a controlled clinical trial. Acta Psychiatr Scand 59:471–480

    Article  Google Scholar 

  • Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer RM (2003) Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28(5):995–1003

    CAS  PubMed  Google Scholar 

  • Löffler S, Löffler-Ensgraber M, Fehsel K, Klimke A (2010a) Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients. Int Clin Psychopharmacol 25(2):101–106

    Article  PubMed  Google Scholar 

  • Löffler S, Klimke A, Kronenwett R, Kobbe G, Haas R, Fehsel K (2010b) Clozapine mobilizes CD34+ hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia. J Clin Psychopharmacol 30(5):591–595

    Article  PubMed  Google Scholar 

  • Lu ML, Lane HY, Lin SK, Chen KP, Chang WH (2004) Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 65(6):766–771

    Article  CAS  PubMed  Google Scholar 

  • Machielsen MW, de Haan L (2009) Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission. Psychopharmacol Bull 42(4):40–52

    PubMed  Google Scholar 

  • Machielsen M, Beduin AS, Dekker N, Genetic Risk and Outcome of Psychosis (GROUP) investigators, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I (2012) Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol 26(1):189–95

    Article  CAS  PubMed  Google Scholar 

  • Mangalore R, Knapp M (2007) Cost of schizophrenia in England. J Ment Health Policy Econ 10:23–41

    PubMed  Google Scholar 

  • McEvoy JP (2007) The costs of schizophrenia. J Clin Psychiatry 68(suppl 14):4–7

    PubMed  Google Scholar 

  • Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S (2003) International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60(1):82–91

    Article  CAS  PubMed  Google Scholar 

  • Miller BJ (2011) Hospitalization for schizophrenia and bipolar disorder: a critical window to recognize and modify mortality risk. Invited editorial. Br Med J 343:d5652

    Article  Google Scholar 

  • Miller BJ, Paschall CB, Svendsen DP (2006) Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv 57(10):1482–1487

    Article  PubMed  Google Scholar 

  • Miller B, Pihlajamaa J, Haukka J, Cannon M, Henriksson M, Hannele H, Huttunen M, Tanskanen A, Lönnqvist J, Suvisaari J, Kirkpatrick B (2010a) Paternal age and mortality in nonaffective psychosis. Schizophr Res 121(1–3):218–226

    Article  PubMed  Google Scholar 

  • Miller BJ, Alaräisänen A, Miettunen J, Järvelin MR, Koponen H, Räsänen P, Isohanni M, Kirkpatrick B (2010b) Advanced paternal age, mortality, and suicide in the general population. J Nervous Mental Dis 198(6):404–411

    Article  Google Scholar 

  • Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70(7):663–671

    Article  CAS  PubMed  Google Scholar 

  • Miller B, Mellor A, Buckley P (2013) Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain Behav Immun 31:82–89

    Article  CAS  PubMed  Google Scholar 

  • Miller BJ, Culpepper N, Rapaport MH (2013) C-reactive protein in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses 21:1–22

    Google Scholar 

  • Moller DE (2000) Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11(6):212–217

    Article  CAS  PubMed  Google Scholar 

  • Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL (2007) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 68(11):1751–1762

    Article  CAS  PubMed  Google Scholar 

  • Mukherjee S, Schnur DB, Reddy R (1989) Family history of type 2 diabetes in schizophrenic patients. Lancet 1:495

    Article  CAS  PubMed  Google Scholar 

  • Murthy P, Chand P (2012) Treatment of dual diagnosis disorders. Curr Opin Psychiatry 25(3):194–200

    Article  PubMed  Google Scholar 

  • Narula PK, Rehan HS, Unni KE, Gupta N (2010) Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 118(1–3):218–223

    Article  PubMed  Google Scholar 

  • O’Keefe CD, Noordsy DL, Liss TB, Weiss H (2003) Reversal of antipsychotic-associated weight gain. J Clin Psychiatry 64(8):907–912

    Article  PubMed  Google Scholar 

  • Obana N, Takagi S, Kinouchi Y et al (2003) Telomere shortening of peripheral blood mononuclear cells in coronary disease patients with metabolic disorders. Intern Med 42:150–153

    Article  CAS  PubMed  Google Scholar 

  • Palmer BA, Pankratz VS, Bostwick JM (2005) The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 62(3):247–253

    Article  PubMed  Google Scholar 

  • Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355:1048–1052

    Article  CAS  PubMed  Google Scholar 

  • Reznik I, Yavin I, Stryjer R, Spivak B, Gonen N, Strous R, Mester R, Weizman A, Kotler M (2004) Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry 37(2):52–56

    Article  CAS  PubMed  Google Scholar 

  • Røge R, Møller BK, Andersen CR, Correll CU, Nielsen J (2012) Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res 140(1–3):204–213

    Article  PubMed  Google Scholar 

  • Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64:1123–1131

    Article  PubMed  Google Scholar 

  • Sampson MJ, Winterbone MS, Hughes JC, Dozio N, Hughes DA (2006) Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. Diabetes Care 29:283–289

    Article  CAS  PubMed  Google Scholar 

  • Schirmbeck F, Zink M (2012) Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol 10(1):88–95

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Shcherbakova I, Neshkova E, Dotsenko V, Platonova T, Shcherbakova E, Yarovaya G (1999) The possible role of plasma kallikrein-kinin system and leukocyte elastase in pathogenesis of schizophrenia. Immunopharmacology 43(2–3):273–279

    Article  CAS  PubMed  Google Scholar 

  • Smith DJ, Langan J, McLean G, Guthrie B, Mercer SW (2013) Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open 3(4):e002808

    Article  PubMed Central  PubMed  Google Scholar 

  • Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH (2007) Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med 24(5):481–485

    Article  CAS  PubMed  Google Scholar 

  • Spivak B, Shabash E, Sheitman B, Weizman A, Mester R (2003) The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. J Clin Psychiatry 64(7):755–760

    Article  CAS  PubMed  Google Scholar 

  • Strassnig M, Ganguli R (2007) Weight loss interventions for patients with schizophrenia. Clin Schizophr Relat Psychoses 1(1):43–53

    Article  Google Scholar 

  • Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690):620–627

    Article  PubMed  Google Scholar 

  • Tovey E, Rampes H, Livingstone C (2005) Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice. J Psychopharmacol 19:207–210

    Article  PubMed  Google Scholar 

  • Waddington JL, Youssef HA, Kinsella A (1998) Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173:325–329

    Article  CAS  PubMed  Google Scholar 

  • Walker AM, Lanza LL, Arellano F, Rothman KJ (1997) Mortality in current and former users of clozapine. Epidemiology 8(6):671–677

    Article  CAS  PubMed  Google Scholar 

  • Wheatley M, Plant J, Reader H, Brown G, Cahill C (2004) Clozapine treatment of adolescents with posttraumatic stress disorder and psychotic symptoms. J Clin Psychopharmacol 24(2):167–173

    Article  CAS  PubMed  Google Scholar 

  • WHO (2009) Global health risks: mortality and burden of disease attributable to selected major risks. ISBN: 978 92 4 156387 1. http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf

  • Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, Tang JS (2006) Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 186(4):572–578

    Article  CAS  Google Scholar 

  • Wu MK, Wang CK, Bai YM, Huang CY, Lee SD (2007) Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv 58(4):544–550

    Article  PubMed  Google Scholar 

  • Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH (2008) Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 299(2):185–193

    Article  CAS  PubMed  Google Scholar 

  • Yu WY, Chang HW, Lin CH, Cho CL (2008) Short telomeres in patients with chronic schizophrenia who show a poor response to treatment. J Psychiatry Neurosci 33(3):244–247

    PubMed Central  PubMed  Google Scholar 

  • Zai G, Müller DJ, Volavka J, Czobor P, Lieberman JA, Meltzer HY, Kennedy JL (2006) Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology (Berl) 188(2):171–182

    Article  CAS  Google Scholar 

  • Zhang X, Hui L, Liu Y, Wang Z-Q, You Y, Miao L, Sun S-L, Guan S-L, Xiang Y, Kosten TR, Zhang ZY (2013) The type 2 diabetes mellitus susceptibility gene IGF2BP2 is associated with schizophrenia in a Han Chinese population. J Clin Psychiatry 74(4):e287–e292

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Health Behavior, Medical College of Georgia, Georgia Regents University, 997 St. Sebastian Way, Augusta, GA, 30912, USA

    Brian J. Miller & Peter F. Buckley

Authors
  1. Brian J. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter F. Buckley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian J. Miller .

Editor information

Editors and Affiliations

  1. Medical College of Georgia Dean’s Office, Georgia Regents University, Augusta, Georgia, USA

    Peter F. Buckley

  2. Department of Psychosis Studies, Institute of Psychiatry, National Psychosis Unit, London, United Kingdom

    Fiona Gaughran

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Miller, B.J., Buckley, P.F. (2014). Medical and Psychiatric Comorbidities: Complicating Treatment Expectations. In: Buckley, P., Gaughran, F. (eds) Treatment–Refractory Schizophrenia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45257-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-45257-4_4

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-45256-7

  • Online ISBN: 978-3-642-45257-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation